Nuklearmedizin. Nuclear medicine最新文献

{"title":"A metastatic melanoma with an atypical low 18F-FDG uptake.","authors":"Laura Ternoy, Pierre Meneret, Xavier Palard-Novello, David Russo","doi":"10.1055/a-2383-2584","DOIUrl":"https://doi.org/10.1055/a-2383-2584","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 2D and 3D lung lobe quantification with Ventilation/Perfusion Ratio.","authors":"Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, Felix M Mottaghy","doi":"10.1055/a-2460-7254","DOIUrl":"https://doi.org/10.1055/a-2460-7254","url":null,"abstract":"<p><p>In this study, standard 2D lung lobe quantification is compared with two 3D lung lobe quantification software tools to investigate the clinical benefit of a 3D approach. The accuracy of 2D versus 3D lung lobe quantification is evaluated based on the calculated numerical ventilation-perfusion ratio (VQR) using a receiver operating curve (ROC) analysis.A study group of 50 consecutive patients underwent a planar lung scintigraphy (anterior/posterior) as well as ventilation/perfusion single photon emission computed tomography (SPECT/CT) to exclude acute pulmonary embolism. All data were acquired with SPECT OPTIMA NM/CT 640 (GE Healthcare). 2D analysis was performed for all ventilation/perfusion scans using a lung analysis tool (Syngo Workstation, Siemens Healthineers). 3D quantification analysis was performed using QLUNG (Q. Lung, Xeleris 4.0, GE Healthcare) and LLQ (Hermes Hybrid 3D Lung Lobar Quantification, Hermes Medical Solutions). The area under the ROC curve (AUC) served as a decision criterion to find the best agreement between clinical PE findings and calculated PE candidates of the 2D and 3D methods. The significance of the ROC curves was evaluated using the DeLong comparison.A significant difference between 2D/3D could be determined. Both 3D approaches showed robust and comparable results. The AUC range of [0.10, 0.67] was given for 2D lobar analysis, QLUNG AUC range revealed in [0.39,0.74] and LLQ AUC range was [0.42,0.72]. Averaged over all lung lobes an AUC=0.39 was given for 2D analysis and AUC=0.58 was given for LLQ/QLUNG.We could demonstrate the better performance of 3D analysis compared to 2D analysis. Consequently, is recommended to use a 3D approach in clinical practice.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing Teratoma Syndrome Revealed By F-18 FDG PET/CT.","authors":"Hatice Uslu, Dilruba Şahin, Mehmet Tarik Tatoglu, Ebru Ibisoglu","doi":"10.1055/a-2273-2350","DOIUrl":"10.1055/a-2273-2350","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"369-370"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid scintigraphy: establishing a clinically useful normal range for 99mTc pertechnetate uptake.","authors":"Michael Grunert, Simone Agnes Schenke, Andrea Konrad, Christina Schütze, Stefan Förster, Burkhard Klemenz, Alexander R Stahl","doi":"10.1055/a-2365-7917","DOIUrl":"10.1055/a-2365-7917","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to establish a normal range for the thyroid uptake derived from ^99mTc pertechnetate scans. In particular, variations of uptake with TSH stimulation and other factors such as urinary iodine concentration are taken into account and compared with the calculation of a raw uptake value.</p><p><strong>Methods: </strong>Clinical multicentric (center A, B and C) prospective study on 125 consecutive healthy patients undergoing thyroid scans for thyroid nodules. Normal functional thyroid status was assured by normal TSH, normal thyroid size, no thyroid antibodies and no symptoms of thyroid functional disorders. Calculations of raw Tc-uptake (uptake) and modified uptake values regarding current TSH value (uptake_TSH1), urinary iodine concentration (uptake_TSH1&uic), gland volume, age, smoking status, weight and tissue thickness ventral to the thyroid were performed.</p><p><strong>Results: </strong>There is a positive correlation of thyroid uptake with TSH allowing for the calculation of a normalized uptake value (uptake_TSH1). The normal range for uptake_TSH1 compares favourable to that for raw uptake in that it yields a clear distinction from thyroid functional disorders. The additional normalization for urinary iodine concentration (uptake_TSH1&uic) may even improve the distinctive power whereas further normalizations such as for gland volume, age and others are not warranted by this study. The 95% CI of uptake_TSH1 for sites A, A&B, and A&B&C were 0.21%-2.06%, 0.22%-2.38% and 0.24%-2.40%.</p><p><strong>Conclusion: </strong>A normal range for the thyroid uptake can be established with respect to the current TSH stimulation. This normalization (uptake_TSH1) overcomes the drawback of raw uptake by yielding a clinically useful parameter with obviously high distinctive power against functional thyroid disorders.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"337-346"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Modern TARE 2023 - from palliative care to a curative treatment alternative].","authors":"Bernhard Gebauer, Federico Collettini, Christian Helmut Pfob, Constantin Lapa","doi":"10.1055/a-2353-5819","DOIUrl":"10.1055/a-2353-5819","url":null,"abstract":"<p><p>Selective internal radiotherapy (SIRT) or transarterial radioembolisation (TARE) is an alternative treatment for hepatocellular carcinoma (HCC) or hepatic metastatic colorectal carcinoma (mCRC) and is now anchored in many guidelines. The article summarises the current guidelines on SIRT/TARE in HCC and mCRC.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"328-336"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 8th and 7th editions of TNM staging in terms of mortality, persistent disease, and response to treatment in patients with differentiated thyroid cancer.","authors":"Golnaz Gholami, Atena Aghaee, Susan Shafiei, Bashir Rasoulian, Emran Askari, Samira Zare Namdar, Seyed Rasoul Zakavi","doi":"10.1055/a-2344-6638","DOIUrl":"10.1055/a-2344-6638","url":null,"abstract":"<p><strong>Objective: </strong>To compare the eighth and seventh editions of TNM staging (TNM-8 and TNM-7) on disease-related mortality, persistent disease, and response to treatment in patients with differentiated thyroid cancer (DTC).</p><p><strong>Methods and materials: </strong>We studied 400 patients (79% female) with DTC with a mean age of 40.93±14.11 years. TNM staging was recorded according to the 7th and 8th editions and patients were followed for at least 1 year and response to therapy was recorded according to ATA response categorization.</p><p><strong>Results: </strong>The mean follow up time was 42.5±15.24 months. Overall, 108 patients (27%) were down-staged using the TNM-8, mainly due to the changes in the age cut-off (14.5%), N (9.25%), and T categorization (3.25%). All patients in stage III and 82.8% in stage IV were down-staged. The mean Tg levels were significantly higher in stages III and IV in TNM-8 compared to TNM-7. Four disease-related death were recorded during follow up, all in stage IV according to TNM-7, while one was in stage II according to TNM-8. One year after treatment, persistent disease was detected in 12% and 77% of patients in stage III according to the 7th and 8th editions, respectively (P= 0.04). Similarly, biochemical incomplete response one year after treatment was seen in 7.3% and 87% in stage III disease using 7th and 8th editions (P = 0.006) that fell to 2.4% and 22% in the last visit respectively (P = 0.04).</p><p><strong>Conclusion: </strong>Persistent disease and incomplete response to therapy were more common in stages III and IV in TNM-8 compared to TNM-7. The eighth edition was a better predictor of persistent disease in stages III and IV disease.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"359-368"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy.","authors":"Esmail Jafari, Reyhaneh Manafi-Farid, Hojjat Ahmadzadehfar, Fatemeh Salek, Narges Jokar, Ahmad Keshavarz, GhasemAli Divband, Habibollah Dadgar, Farshad Zohrabi, Majid Assadi","doi":"10.1055/a-2365-8113","DOIUrl":"10.1055/a-2365-8113","url":null,"abstract":"<p><strong>Background: </strong>In this study, we sought to identify the clinical baseline characteristics and pre-therapy 68Ga-PSMA PET derived parameters that can have impact on PSA (biochemical) response, OS and PSA PFS in patients with metastatic castration-resistant prostate cancer (mCRPC) who undergo RLT with [177Lu]Lu-PSMA-617.</p><p><strong>Methods: </strong>Various pre-treatment clinical and PSMA PET derived parameters were gathered and computed. We used PSA response as the criteria for more than a 50% decrease in PSA level, and OS and PSA PFS as endpoints. We assessed the collected parameters in relation to PSA response. Additionally, we employed univariable Cox regression and Kaplan-Meier analysis with log rank to evaluate the influence of the parameters on OS and PFS.</p><p><strong>Results: </strong>A total of 125 mCRPC patients were included in this study. The median age was 68 years (range: 49-89). Among the cases, 77 patients (62%) showed PSARS, while 48 patients (38%) did not show PSA response. The median OS was 14 months (range: 1-60), and the median PSA-PFS was 10 months (range: 1-56). Age, prior history of chemotherapy, and SUVmax had a significant impact on PSA response (p<0.05). PSA response, RBC count, hemoglobin, hematocrit, neutrophil to lymphocyte ratio (NLR), alkaline phosphatase (ALP), number of metastases, wbPSMA-TV, and wbTL-PSMA significantly affected OS. GS, platelet count, NLR, and number of metastases were found to have a significant impact on PSA PFS.</p><p><strong>Conclusion: </strong>We have identified several baseline clinical and PSMA PET derived parameters that can serve as prognostic factors for predicting PSA response, OS, and PSA PFS after RLT. Based on the findings, we believe that these clinical baseline characteristics can assist nuclear medicine specialists in identifying RLT responders who have long-term survival and PFS.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"347-358"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Langerhans Cell Histiocytosis-Associated Vertebra Plana on FDG PET.","authors":"Christopher Ruggiero, Danielle Maracaja, Steven P Rowe","doi":"10.1055/a-2438-7469","DOIUrl":"https://doi.org/10.1055/a-2438-7469","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor on 18F-FDG PET/CT.","authors":"Gege Zhao, Zhongke Huang","doi":"10.1055/a-2383-2527","DOIUrl":"https://doi.org/10.1055/a-2383-2527","url":null,"abstract":"<p><p>A 65-year-old man, who denied a smoking history, presented with chest distress and pain persisting for over a week. A contrast-enhanced chest CT scan revealed a large irregular mass in the right thoracic cavity with heterogeneous enhancement. The 18F-FDG PET/CT showed a large mass in the right thoracic cavity with heterogeneous markedly high FDG uptake. The patient subsequently underwent a bronchoscopic-guided mucosal biopsy at the opening of the right upper lobe. The histological and immunohistochemical findings were consistent with thoracic SMARCA4-deficient undifferentiated tumor.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of whole-body 18F-FDG-PET/CT with 18F-FDG-PET/CT limited to skull base to upper abdomen for primary staging of lung cancer - a retrospective explorative analysis.","authors":"Lukas Schulz, Georg-Christian Funk, Klaus Kirchbacher, Elena Egger, Nino Müser, Siroos Mirzaei","doi":"10.1055/a-2438-7278","DOIUrl":"https://doi.org/10.1055/a-2438-7278","url":null,"abstract":"<p><p>The gold standard for ruling out distant metastases as part of primary staging in lung cancer is whole-body ¹⁸F-FDG-PET/CT, but this method is resource-intensive. Recent evidence suggests that examining only the thorax and upper abdomen may be sufficient 1 2 3. If a limited ¹⁸F-FDG-PET/CT approach proves effective for proper staging, it could lead to quicker examinations and reduced radiation exposure. This study aimed to determine whether limited ¹⁸F-FDG-PET/CT is adequate for the primary staging of lung cancer.In this study, a retrospective analysis of 161 patients (87 men, 74 women; age range 31-88 y) with recent or suspected lung cancer who had undergone a whole-body ¹⁸F-FDG-PET/CT examination for primary staging at our clinic between 2018 and 2022 was conducted. None of these patients showed evidence of extrathoracic metastases before the ¹⁸F-FDG-PET/CT examination. The images were divided into three regions: \"head-neck\" (HN), \"thorax-upper abdomen\" (TUA), and \"lower abdomen-hip\" (LAH). TNM staging based on the HN plus TUA region was compared with TNM staging based on the whole body.Among the 161 subjects, 7 (4%) showed malignancy-suspect lesions in HN, 110 (68%) in TUA and 7 (4%) had suspected distant metastases in LAH. The TNM staging based on HN plus TUA corresponded to TNM staging based on the whole body in 161 (100%) examinations. This finding aligns with similar results in previous literature. ¹⁸F-FDG-PET/CT limited to HN and TUA yielded accurate staging in all cases. Adopting this method could facilitate the examination and correct staging of more individuals, reducing exam waiting times and physician reporting time and minimising radiation exposure.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}